This story was updated on June 8 to include a link to an FDA document about eligibility.
By Tom Rosenthal
Clinicians should not avoid prescribing nirmatrelvir-ritonavir (Paxlovid, Pfizer) to treat mild to moderate COVID-19 out of fear of or confusion over potential drug–drug interactions, Infectious Diseases Society of America (IDSA) experts said in a media briefing to promote the organization’s recently updated COVID-19 treatment guidelines on the drug’s usage.
In developing the